Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) Richard Pye tells Proactive Investors 2017 was a 'landmark' year for them however a number of critical milestones lie ahead of them.
Top-line results for ezutromid, a potential breakthrough treatment for sufferers of Duchenne Muscular Dystrophy (DMD), a fatal wasting disease that affects boys are expected to be released in Q3.
The read-out from the Phase II proof-of-concept study is expected from September onwards; however, interim data has already revealed a statistically significant reduction in muscle damage and inflammation in patients after just 24-weeks.
Meet Peninsula Mines Ltd and Silver City Minerals Ltd at our event,Sydney, 07 May 2018.Register here >>